Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
14/WM/0170	154982	A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis	Number Agreed	2	2	Not Available / Not Agreed		3	12/01/2016	Recruitment Finished
14/EE/1235	159181	A PHASE 2 RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE? INFLUENZA A INFECTION	Number Agreed	2	2	Not Available / Not Agreed		0	02/02/2016	Withdrawn By Host
14/NW/0119	148925	A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabap	Number Agreed	10	10	Not Available / Not Agreed		0	16/03/2016	Withdrawn By Sponsor
14/SC/0033	146569	PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	6	6	Not Available / Not Agreed		5	26/01/2016	Recruitment Finished
15/SW/0197	181752	GO29432: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCE	Number Agreed	4	4	Not Available / Not Agreed		0	19/04/2016	Recruitment Finished
14/LO/0324	146711	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin? in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, includin	Number Agreed	3	3	Not Available / Not Agreed		1	06/01/2016	Recruitment Finished
15/LO/0967	178036	iNNOVATE Study: A randomized, double-blind, placebo-controlled, phase 3 study of ibrutinib or placebo in combination with Rituximab in Subjects with Waldenstr?m?s Macroglobulinemia	Number Agreed	5	5	Not Available / Not Agreed		0	13/01/2016	Recruitment Finished
14/NE/1214	162696	A Randomised, OpenLabel, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced NonSquamous No	Number Agreed	6	6	Not Available / Not Agreed		0	10/06/2016	Recruitment Finished
13/SC/0490	135889	A PHASE III, Randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of lebrikizumab in adolescent patients with severe uncontrolled asthma who are on inhaled corticosteroids and a second controller medicat	Number Agreed	3	3	Not Available / Not Agreed		2	30/06/2016	Withdrawn By Sponsor
13/NI/0148	102251	A phase II, randomised, double blind, placebo controlled, multicentre trial to assess the oral corticosteroidsparing effect of lebrikizumab in patients with with severe corticosteroiddependant asthma	Number Agreed	12	12	Not Available / Not Agreed		10	30/06/2016	Withdrawn By Sponsor
16/LO/0026	195795	A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS 9883/Emtricitabine/Tenofovir Alafena	Number Agreed	6	6	Not Available / Not Agreed		3	23/06/2016	Recruitment Finished
16/LO/0029	195696	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Na?ve Adults	Number Agreed	3	3	Not Available / Not Agreed		5	15/07/2016	Recruitment Finished

15/LO/1163	181430	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens Containing ABC/£TC	Number Agreed	6	6	Not Available / Not Agreed		6	29/05/2016	Recruitment Finished
13/EM/0349	133741	A randomized Phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen receptor-positive advanced or metastatic breast cancer	Number Agreed	3	3	Not Available / Not Agreed		1	13/09/2016	Recruitment Finished
13/EM0239	116638	Remifentanil Intravenous Patient Controlled Analgesia (PCA) versus Intramuscular Pethidine for Pain Relief in Labour: A Randomised Controlled Trial	Number Agreed	40	40	Not Available / Not Agreed		2	05/09/2016	Recruitment Finished
14/YH/1199	153953	GALACTIC: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL	Number Agreed	83	83	Not Available / Not Agreed		4	23/11/2016	Recruitment Finished
14/SC/0033	146569	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	6	6	Not Available / Not Agreed		0	04/11/2016	Withdrawn By Sponsor
14/SC/0032	142458	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615 IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	6	6	Not Available / Not Agreed		0	04/11/2016	Withdrawn By Sponsor
14/LO/0324	146711	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquinr in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, includin	Number Agreed	3	3	Not Available / Not Agreed			06/01/2016	Recruitment Finished
11/LO/1570	80305	CHEMO-T - Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus Gemcitabine and Cisplatin (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II study	Number Agreed	4	4	Not Available / Not Agreed		0	01/12/2016	Withdrawn By Sponsor
12/LO/1078	97486	A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma.	Number Agreed	5	5	Not Available / Not Agreed		8	06/12/2016	Recruitment Finished
13/LO/0108	112000	LEGEND - A Randomised Phase II Study Comparing Lenalidomide plus Rituximab, Gemcitabine and Methylprednisolone (L-RGEM) to Rituximab, Gemcitabine, Methylprednisolone and Cisplatin (RGEMP) in Second Line Treatment of Diffuse Large B-Cell Lymphoma (DLB	Number Agreed	5	5	Not Available / Not Agreed		2	16/12/2016	Withdrawn By Sponsor
12/NS/0093	112403	Vault or Uterine prolapse surgery Evaluation. Two parallel randomised controlled trials of surgical options for upper compartment (vauilt or uterine) pelvic organ prolapse	Number Agreed	10	10	Not Available / Not Agreed		7	06/12/2016	Recruitment Finished
12/SC/0592	98570	An Observational Post authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of	Number Agreed	30	30	Not Available / Not Agreed		32	31/01/2016	Recruitment Finished